Insmed: Company Presses On With Further POC PAH Treatment Data

Group 1 - Insmed Incorporated (NASDAQ: INSM) announced positive results from its phase 2b study of treprostinil palmitil inhalation powder (TPIP) for treating pulmonary arterial hypertension (PAH) [2] - The study achieved success in both primary and secondary endpoints, indicating the drug's potential effectiveness [2] Group 2 - The Biotech Analysis Central service offers in-depth analysis of pharmaceutical companies, including a library of over 600 biotech investing articles and a model portfolio of small and mid-cap stocks [1][2] - The service is available for $49 per month, with a discounted yearly plan at $399, providing a 33.50% savings [1]